Synthesis and single-molecule imaging reveal stereospecific enhancement of binding kinetics by the antitumor eEF1A antagonist SR-A3
H. Wang, H. Yang, M. Holm, K. Oltion, H. Tom, A. A. Q. Al-Khdhairawi, J.-F. F. Weber, S. Blanchard, D. Ruggero, J. Taunton
This study synthesizes and characterizes SR-A3, a stereoisomer of a natural product, showing enhanced binding kinetics and therapeutic efficacy in a mouse lymphoma model.
bioRxiv · Oct 6, 2020Pharmacology & Toxicology